Genzyme expects flat earnings during first quarter
This article was originally published in Scrip
Executive Summary
Genzyme expects its first-quarter revenues to be flat owing to the challenging economic environment and regulatory approval delays for Myozyme (alglucosidase alfa) in the previous quarter. The firm said earnings would grow during the second quarter when it expects two key regulatory approvals for the Pompe disease therapy.